Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway

Abstract

Abstract The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested.

Keywords

• Ivermectin
• Endectocide
• Clinical trials
• Clinical development
• Anopheles